Walleye Capital LLC Sells 40,725 Shares of ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC lessened its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 56.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,284 shares of the specialty pharmaceutical company’s stock after selling 40,725 shares during the quarter. Walleye Capital LLC owned approximately 0.14% of ANI Pharmaceuticals worth $2,094,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of ANIP. National Bank of Canada FI bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at $79,000. GAMMA Investing LLC boosted its position in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after purchasing an additional 881 shares in the last quarter. Rafferty Asset Management LLC bought a new stake in ANI Pharmaceuticals during the fourth quarter valued at about $200,000. Bridgefront Capital LLC bought a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at about $204,000. Finally, Mesirow Financial Investment Management Inc. bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $206,000. Institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

ANIP has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. HC Wainwright reissued a “buy” rating and issued a $93.00 price objective (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Guggenheim reissued a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, Piper Sandler reissued an “overweight” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $84.75.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $92.53 on Friday. The stock has a 50-day moving average of $72.83 and a two-hundred day moving average of $66.78. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $92.65. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The stock has a market cap of $2.01 billion, a P/E ratio of -120.17 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the previous year, the company posted $1.02 earnings per share. The company’s revenue was up 53.2% compared to the same quarter last year. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,763 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $91.10, for a total transaction of $160,609.30. Following the completion of the sale, the senior vice president directly owned 62,896 shares in the company, valued at approximately $5,729,825.60. The trade was a 2.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Matthew J. Leonard sold 2,528 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $90.62, for a total transaction of $229,087.36. Following the transaction, the director owned 6,864 shares of the company’s stock, valued at $622,015.68. This represents a 26.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 405,538 shares of company stock worth $35,690,131. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.